Evaluation of clinical practice guidelines on outcome of infection in medical intensive care unit patients

Infectious Diseases in Clinical Practice

Volumn 8, Issue 2, 1999, Pages 97-106

  Brooks, Alison ^a,d   Ekleberry, Ann ^a,b,d   McMahon, James ^a,b,d   Begle, Robert ^a,c,d,e   Johnson, Matthew ^a,d   Rizzo, John ^a,f   Zervos, Marcus J ^a,b,d,e  

^a Department of Medicine ^*  (United States)

^b Division of Infectious Diseases   (United States)

^c Div Pulmon and Critical Care Med   (United States)

^d WILLIAM BEAUMONT HOSPITAL   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAMASE; CEFAZOLIN; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; MACROLIDE; METRONIDAZOLE; NAFCILLIN; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN; SULTAMICILLIN; TIMENTIN; TOBRAMYCIN; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; CLINICAL TRIAL; COST CONTROL; DRUG COST; FEMALE; HOSPITAL INFECTION; HUMAN; INFECTION; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE;

EID: 0032908275     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199902000-00009     Document Type: Article

References (71)

1. Barza M. A model of the transmission of antibiotic-resistant bacteria in the intensive care unit. New Horizons 1996;4:333-7.
2. American Society for Microbiology Task Force on Antibiotic Resistance. Report of the ASM Task Force on Antibiotic Resistance. Antimicrob Agents Chemother 1995;39 Suppl:2-23.
3. Pallares R, Dick R, Wenzel RP, et al. Trends in antimicrobial utilization at a tertiary teaching hospital during a 15-year period (1978-1992). Infect Control Hosp Epidemiol 1993;14:376-82.
4. Itokazu GS, Quinn JP, Bell-Dixon C, et al. Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. Clin Infect Dis 1996;23:779-84.
5. Jones RN. The current and future impact of antimicrobial resistance among nosocomial bacterial pathogens. Diagn Microbiol Infect Dis 1992;15 Suppl:3S-10S.
6. Buckwold FJ, Ronald AR. Antimicrobial misuse-effects and suggestions for control. J Antimicrob Chemother 1979;5:129-36.
7. Jacobson KL, Cohen SH, Inciardi JF, et al. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporin in group I β-lactamase-producing organisms. Clin Infect Dis 1995;21: 1107-13.
8. Muder RR, Brennen C, Goetz AM, et al. Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center. Antimicrob Agents Chemother 1991;35:256-8.
9. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;8: 585-90.
10. Schaberg DR, Rubens CE, Alford RH, et al. Evolution of antimicrobial resistance and nosocomial infection. Am J Med 1981;70:445-8.
11. Martin MA. Nosocomial infections in intensive care units: an overview of their epidemiology, outcome, and prevention. New Horizons 1993;1:162-70.
12. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, et al. The prevalence of nosocomial infection in intensive care units in Europe. JAMA 1995;274:639-44.
13. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991;91(3B Suppl):72S-75S.
14. Pinner RW, Teutsch SM, Simonsen L, Klug LA, Graber JM, Clarke MJ, Berkelman RL. Trends in infectious diseases mortality in the United States. JAMA 1996;275:189-93.
15. Jarvis WR. Preventing the emergence of multidrug-resistant microorganisms through antimicrobial use controls: the complexity of the problem. Infect Control Hosp Epidemiol 1996;17:490-5.
16. North D. Controlling the costs of antibiotic resistance. Clin Ther 1993;15:3-11.
17. Davis DA, Thomson MA, Oxman AD, et al. Changing physician performance. JAMA 1995;274:700-5.
18. Bowen OR. Shattuck lecture: what is quality care? N Engl J Med 1987;316:1578-80.
19. Wennberg JE. Variations in medical practice and hospital costs. Conn Med 1985;49:444-53.
20. Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med 1990;113:147-54.
21. The indicator measurement system. Joint Commission on Accreditation of Healthcare Organizations; 1996.
22. Benson DS. Measuring outcomes in ambulatory care. Chicago: American Hospital Association; 1992.
23. Walton M. The Deming management method. New York: Putman; 1986.
24. Rizzo JA, Sindelar JL. Medical practice guidelines and the efficient allocation of resources. In: Health care policy and regulation. Norwell (MA): Kluwer Academic Publishing; p. 182-99.
25. Audet AM, Greenfield S, Field M. Medical practice guidelines: current activities and future directions. Ann Intern Med 1990;113:709-14.
26. Pearson SD, Goulart-Fisher D, Lee TH. Critical pathways as a strategy for improving care: problems and potential. Ann Intern Med 1995;123:941-8.
27. Sox HC. Practice guidelines: 1994. Am J Med 1994;97: 205-7.
28. Ellroclt AG, Conner L, Riedinger M, et al. Measuring and improving physician compliance with clinical practice guidelines. Ann Intern Med 1995;122:277-82.
29. Berwick DM. Eleven worthy aims for clinical leadership of health system reform. JAMA 1994;272:797-802.
30. Shane R. Development and implementation of practice guidelines. Hosp Formul 1994;29:711-9.
31. Kritchevsky SB, Simmons BP. Continuous quality improvement: concepts and applications for physician care. JAMA 1991;266:1817-23.
32. Horn S, Hopkins DS. Clinical practice improvement: a new technology for developing cost-effective health care. New York: Faulkner and Gray; 1992.
33. Spath PL. Clinical pathways: tools for outcomes management. Chicago: American Hospital Association; 1994.
34. Leebov W, Scott G. Service quality improvement: the customer satisfaction strategy for health care. Chicago: American Hospital Association; 1994.
35. The 1995 Medical Outcomes and Guidelines Sourcebook. New York: Faulkner and Gray; 1994.
36. Fliegelman R. Development of a clinical algorithm using continuous quality improvement. Pharm Ther 1996:490-501.
37. Schriefer J. The synergy of pathways and algorithms: two tools work better than one. Jt Comm J Qual Improv 1994;20:485-99.
38. Bohnen JMA, Solomkin JS, Dellinger P, et al. Guidelines for clinical care: anti-infective agents for intra-abdominal infection. Arch Surg 1992;127:83-9.
39. Niederman MS, Bass JB Jr, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993;148:1418-26.
40. Epstein RS, Sherwood LM. From outcomes research to disease management: a guide for the perplexed. Ann Intern Med 1996;124:832-7.
41. Fang GD, Fine J, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. Medicine 1990;69:307-16.
42. Campbell GD, Niederman MS, Broughton WA, et al. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies - a consensus statement. Am J Respir Crit Care Med 1996;153:1711-25.
43. Garner JS, Jarvis WR, Emori TG, et al. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16:128-40.
44. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Preventing the spread of vancomycin resistance: report from the hospital infection control practices advisory committee - comment period and public meeting: notice. Fed Registr 1994;59:25758-63.
45. Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991;100:1619-36.
46. Couch JB, Nash DB. Severity of illness measures: opportunities for clinicians. Ann Intern Med 1988;109:771-3.
47. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 2nd ed. Approved standard. NCCLS document M7-A2. Villanova (PA): National Committee for Clinical Laboratory Standards; 1990.
48. Lederberg J, Shope RE, Oaks SC, editors. Emerging infections: microbial threats to health in the United States. Washington (DC): National Academy Press; 1992. p. 94.
49. U.S. Department of Health and Human Services. Healthy people 2000: national health promotion and disease prevention objectives. Washington (DC): U.S. Government Printing Office; 1990. p. 526.
50. Centers for Disease Control and Prevention. Addressing emerging infectious disease threats: a prevention strategy for the United States. MMWR 1994;43:1-18.
51. Leibovici L, Konisberger H, Pitlik SD, et al. Patients at risk for inappropriate antibiotic treatment of bacteremia. J Intern Med 1992;231:371-4.
52. Archibald L, Phillips L, Monnet D, et al. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997;24:211-5.
53. McGowan JE Jr. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infect Control Hosp Epidemiol 1994;15:478-83.
54. Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial resistant microorganisms in hospitals. JAMA 1996;275:234-40.
55. Schentag JJ, Ballow CH, Fritz AL, et al. Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory. Diagn Microbiol Infect Dis 1993;16:255-64.
56. Bartlett JG, Brieman RF, Mandell LA, et al. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998;26:811-38.
57. O'Grady NP, Barie PS, Bartlett JG, et al. Practice guidelines for evaluating new fever in critically ill adult patients. Clin Infect Dis 1998;26:1042-59.
58. Evans RS, Burke JP, Classen DC, et al. Computerized identification of patients at high risk for hospital-acquired infection. Am J Infect Control 1992;20:4-10.
59. Johnston ME, Langton KB, Haynes RB, et al. Effects of computer-based clinical decision support systems on clinician performance and patient outcome. Ann Intern Med 1994;120:135-42.
60. Johnson N, Last J. Understanding and using technology assessments. Pharm Ther 1995:477-86.
61. Hedblom EC. Pharmacoeconomic and outcomes data in the managed care formulary decision-making process. Pharm Ther 1995:462-73.
62. Bankowitz RA, McNeil MA, Challinor SM, et al. A computer-assisted medical diagnostic consultation service. Ann Intern Med 1989;110:824-32.
63. Evans RS, Pestotnik SL, Classen DC, et al. Development of an automated antibiotic consultant. MD Comput 1993; 10:17-22.
64. de Latorre FJ, Pont T, Ferrer A, et al. Pattern of tracheal colonization during mechanical ventilation. Am J Respir Crit Care Med 1995;152:1028-33.
65. Pestotnik SL, Classen DC, Evans RS, et al. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann Intern Med 1996;124:884-90.
66. Acar JF, Goldstein FW, Menard R. et al. Strategies in aminoglycoside use and impact on resistance. Am J Med 1986;80(6B Suppl):82-7.
67. Gerding DN, Larson TA. Aminoglycoside resistance in gram-negative bacilli during increased amikacin use. Am J Med 1985;79(1A Suppl):1-7.
68. Moody MM, deJongh CA, Schimpff SC, et al. Long term amikacin use: effects on aminoglycoside susceptibility patterns of gram-negative bacilli. JAMA 1982;248:1199-1202.
69. McGowan JE Jr. Minimizing antimicrobial resistance in hospital bacteria: can switching or cycling drugs help? Infect Control Hosp Epidemiol 1986;7:573-6.
70. Niederman MS. Is "crop rotation" of antibiotics the solution to a "resistant" problem in the ICU [editorial; comment]? Am J Respir Crit Care Med 1997;156:1029-31.
71. Kollef MH, Vlasnik J, Sharpless L, et al. Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia [see comments]. Am J Respir Crit Care Med 1997;156:1040-8.